1. EVERBIO II
Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES. They were followed for 9 months.
Results
Primary outcome, in-stent LLL at 9 months, for BVS vs. BES vs. EES: 0.28 vs vs mm, p = 0.30
Acute recoil: 9.5% vs. 6.9% vs. 6.2%, p < 0.01; restenosis at 9 months: 6% vs. 6% vs. 7%; p = 1.0
TLR: 24% vs. 19% vs. 30%, p = 0.99; stent thrombosis: 1% vs. 0% vs. 0%, p = 0.33 
Conclusions
Among patients with CAD, BVS, BES, and EES had similar angiographic outcomes at 9 months in this single-center study, despite a higher rate of acute recoil immediately post-implant; stent thrombosis rates were low and similar
This trial presents early comparative data between BVS, BES, and currently used 2nd generation DES
Puricel S, et al. J Am Coll Cardiol 2015;65: